Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients

医学 抗组胺药 内科学 无容量 肿瘤科 癌症 相伴的 危险系数 彭布罗利珠单抗 易普利姆玛 免疫疗法 药理学 置信区间
作者
Eda Eylemer Mocan,Emre Yekedüz,Göktürk Karataş,Satı Coşkun Yazgan,Elif Berna Köksoy,Filiz Çay Şenler,Güngör Utkan,Ahmet Demirkazık,Hakan Akbulut,Yüksel Ürün
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
标识
DOI:10.1097/cad.0000000000001498
摘要

Histamine and H1 receptors play a crucial role in the tumor microenvironment. Preclinical data showed that concomitant use of antihistamines and immune checkpoint inhibitors (ICIs) might increase the effect of ICIs. This study aimed to evaluate the impact of antihistamines on the oncological outcomes of ICIs. This retrospective study was conducted in a tertiary cancer center. Advanced cancer patients treated with ICIs were included in this study. A total of 133 patients receiving ICIs in the metastatic setting were included. Melanoma (33.1%) was the most common tumor type. The most common ICI was nivolumab (63.2%). Fifty-five (38.4%) patients received antihistamines concomitantly with ICIs. The most common antihistamine was pheniramine (85.5%). The median progression-free survival (PFS) (8.2 vs. 5.1 months, P = 0.016) and overall survival (OS) (16.2 vs. 7.7 months, P = 0.002) were longer in patients receiving antihistamines concomitantly with ICIs. In multivariate analysis, PFS [hazard ratio (HR) = 0.63, 95% CI: 0.40-0.98, P = 0.042] and OS (HR = 0.49, 95% CI: 0.29-0.81, P = 0.006) were also better in those patients after adjusting for confounding factors, such as performance status, bone or liver metastasis, and concurrent chemotherapy. This study suggested that antihistamines may enhance the efficacy of ICIs in patients with advanced cancer. If validated in prospective trials, antihistamines and ICIs combinations might be new options to improve oncological outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
J_C_Van完成签到,获得积分10
刚刚
橘子树完成签到,获得积分10
1秒前
玛斯特尔完成签到,获得积分10
1秒前
hearz发布了新的文献求助10
1秒前
ZSH完成签到,获得积分10
2秒前
Litoivda完成签到 ,获得积分10
4秒前
暮雨完成签到,获得积分10
5秒前
DOGDAD完成签到,获得积分10
7秒前
英俊的铭应助温柔翰采纳,获得10
7秒前
英姑应助薛建伟采纳,获得10
7秒前
如云完成签到,获得积分20
8秒前
你说的完成签到 ,获得积分10
8秒前
Jasper应助大脸猫4811采纳,获得10
9秒前
hearz完成签到,获得积分10
10秒前
11秒前
P2JY完成签到,获得积分10
11秒前
leiiiiiiii完成签到,获得积分10
11秒前
Bake完成签到 ,获得积分10
13秒前
14秒前
yuan完成签到,获得积分10
14秒前
论文多多完成签到,获得积分10
15秒前
15秒前
Acid完成签到 ,获得积分10
15秒前
1111111111111发布了新的文献求助10
16秒前
linlinyilulvdeng完成签到,获得积分10
16秒前
斯文败类应助历史雨采纳,获得10
17秒前
FashionBoy应助吃个大笼包采纳,获得10
19秒前
海阔天空发布了新的文献求助10
20秒前
薛建伟发布了新的文献求助10
21秒前
高高代珊发布了新的文献求助10
22秒前
害羞的墨镜完成签到,获得积分10
22秒前
lalala发布了新的文献求助10
22秒前
23秒前
guojingjing完成签到,获得积分10
23秒前
打打应助科多兽骑士采纳,获得10
24秒前
angela完成签到,获得积分10
24秒前
24秒前
潇洒的茗茗完成签到 ,获得积分10
26秒前
脂肪小米粥完成签到,获得积分10
27秒前
小幸运完成签到,获得积分10
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038657
求助须知:如何正确求助?哪些是违规求助? 3576306
关于积分的说明 11375198
捐赠科研通 3306108
什么是DOI,文献DOI怎么找? 1819379
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066